• World-first ischemic ventricular tachycardia (VT) ablation successfully performed under real-time MRI guidance
• UVA Health joins VISABL-AFL clinical trial to support FDA approval
• World's first preclinical in vivo PFA ablation performed in the ventricle under real-time MRI guidance

Imricor Medical Systems, Inc. (ASX: IMR) has released its Q4 CY25 Quarterly Activities Report and Appendix 4C, highlighting significant regulatory, clinical, and commercial milestones. Key achievements include the successful world-first performance of ischemic ventricular tachycardia (VT) ablation under real-time MRI guidance, the addition of UVA Health to the VISABL-AFL clinical trial to support FDA approval, and the world's first preclinical in vivo pulsed field ablation (PFA) in the ventricle under real-time MRI guidance using Imricor's second-generation Vision-MR Ablation Catheter. The company also reported progress in its international market expansion, with in-market registration of 2nd generation devices in the Middle East and the planned commencement of routine atrial flutter ablations at Charité Hospital in Berlin, which will also become the 2nd site in Europe to join the VISABL-VT clinical trial. Imricor's financial position remains strong, with total cash and short-term investments of US$40.8 million as of 31 December 2025. The company's focus is on execution and conversion of existing opportunities rather than pipeline expansion, as it positions itself to redefine the treatment of complex arrhythmias with its innovative MRI-guided cardiac ablation solutions.

Imricor is well positioned to redefine how complex arrhythmias are treated, safely, precisely, and without reliance on x-ray, as regulatory, clinical, and commercial milestones increasingly converge.